Table 1.
Baseline demographic and disease characteristics of participants (population for efficacy analysis)
| 2.5% BPO gel | 5% BPO gel | |
|---|---|---|
| No. of cases (%) | No. of cases (%) | |
| No. of subjects analyzed | 231 | 227 |
| Sex | ||
| Male | 72 (31.2) | 72 (31.7) |
| Female | 159 (68.8) | 155 (68.3) |
| Age (years) | ||
| 12–15 | 34 (14.7) | 34 (15.0) |
| 16–20 | 75 (32.5) | 62 (27.3) |
| 21–25 | 56 (24.2) | 62 (27.3) |
| 26–30 | 22 (9.5) | 34 (15.0) |
| 31–35 | 27 (11.7) | 20 (8.8) |
| 36–40 | 13 (5.6) | 8 (3.5) |
| 41–45 | 1 (0.4) | 5 (2.2) |
| 46–49 | 3 (1.3) | 2 (0.9) |
| Average | 22.9 | 23.0 |
| SD | 7.3 | 7.5 |
| History of hypersensitivity | ||
| Yes | 14 (6.1) | 22 (9.7) |
| No | 217 (93.9) | 205 (90.3) |
| Concomitant drugs | ||
| Yes | 187 (81.0) | 181 (79.7) |
| No | 44 (19.0) | 46 (20.3) |
| Unknown | 0 | 0 |
| Concomitant therapies | ||
| Yes | 36 (15.6) | 31 (13.7) |
| No | 193 (83.5) | 193 (85.0) |
| Unknown | 2 (0.9) | 3 (1.3) |
| No. of IL at baseline | ||
| Median | 12.0 | 11.0 |
| Range | 5–39 | 5–40 |
| No. of TL at baseline | ||
| Median | 35.0 | 37.0 |
| Range | 6–127 | 7–130 |
| No. of non‐IL at baseline | ||
| Median | 21.0 | 21.0 |
| Range | 1–99 | 1–97 |
| No. of nodules/cysts at baseline | ||
| Median | 0.0 | 0.0 |
| Range | 0–1 | 0–2 |
BPO, benzoyl peroxide; IL, inflammatory lesions; SD, standard deviation; TL, total lesions.